Genotoxicity and subchronic toxicity of Sophorae radix in rats: Hepatotoxic and genotoxic potential

Regulatory Toxicology and Pharmacology

Volumn 71, Issue 3, 2015, Pages 379-387

  Che, Jeong Hwan ^a,b   Yun, Jun Won ^a   Kim, Yun Soon ^a   Kim, Seung Hyun ^a   You, Ji Ran ^a   Jang, Ja June ^c   Kim, Hee Chan ^b   Kim, Hyeon Hoe ^c   Kang, Byeong Cheol ^a,b,c  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Anemia; Genotoxicity; Hepatotoxicity; Liver; Sophorae radix; Subchronic

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CLASTOGEN; PLANT EXTRACT; SOPHORAE RADIX; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHROMOSOME ABERRATION; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; ERYTHROCYTE; FEMALE; GENOTOXICITY; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; IN VIVO STUDY; LIVER INJURY; LIVER TOXICITY; LIVER WEIGHT; MALE; MICRONUCLEUS TEST; NONHUMAN; ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RAT; SUBCHRONIC TOXICITY; TOXICITY; ANIMAL; BLOOD; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; EATING; FISCHER 344 RAT; MEDICINAL PLANT; MICRONUCLEUS; MUTAGEN TESTING; NO-OBSERVED-ADVERSE-EFFECT LEVEL; ORAL DRUG ADMINISTRATION; PHYTOTHERAPY; PROCEDURES; RISK ASSESSMENT; SOPHORA; TIME; TOXICITY TESTING;

RATTUS;

ADMINISTRATION, ORAL; ANEMIA; ANIMALS; BIOMARKERS; BODY WEIGHT; CHROMOSOME ABERRATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; EATING; FEMALE; MALE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; RATS, INBRED F344; RISK ASSESSMENT; SOPHORA; TIME FACTORS; TOXICITY TESTS, SUBCHRONIC;

EID: 84923274529     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2015.01.012     Document Type: Article

References (48)

1. Caldwell S.H., Hoffman M., Lisman T., Macik B.G., Northup P.G., Reddy K.R., Tripodi A., Sanyal A.J. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006, 44:1039-1046.
2. Chang M.S., Xiao J.G., Chiou G.C. Prevention of ocular inflammation by matrine, prednisolone, and cyclooxygenase and lipoxygenase inhibitors. Zhongguo Yao Li Xue Bao 1991, 12:121-125.
3. Che J.H., Yun J.W., Cho E.Y., Kim S.H., Kim Y.S., Kim W.H., Park J.H., Son W.C., Kim M.K., Kang B.C. Toxicologic assessment of Paecilomyces tenuipes in rats: renal toxicity and mutagenic potential. Regul. Toxicol. Pharmacol. 2014, 70:527-534.
4. Chen Q., Tang S., Jin X., Zou J., Chen K., Zhang T., Xiao X. Investigation of the genotoxicity of quinocetone, carbadox and olaquindox in vitro using Vero cells. Food Chem. Toxicol. 2009, 47:328-334.
5. Chen T., Mei N., Fu P.P. Genotoxicity of pyrrolizidine alkaloids. J. Appl. Toxicol. 2010, 30:183-196.
6. Deng H., Luo H., Huang F., Li X., Gao Q. Inhibition of proliferation and influence of proto-oncogenes expression by matrine in C6 cell. Zhong Yao Cai 2004, 27:416-419.
7. Fan P., Lou H. Effects of polyphenols from grape seeds on oxidative damage to cellular DNA. Mol. Cell. Biochem. 2004, 267:67-74.
8. Föller M., Feil S., Ghoreschi K., Koka S., Gerling A., Thunemann M., Hofmann F., Schuler B., Vogel J., Pichler B., Kasinathan R.S., Nicolay J.P., Huber S.M., Lang F., Feil R. Anemia and splenomegaly in cGKI-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:6771-6776.
9. Garcia-Pagan J.C., De Gottardi A., Bosch J. Review article: the modern management of portal hypertension-primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. Aliment. Pharmacol. Ther. 2008, 28:178-186.
10. Gonzalez-Casas R., Jones E.A., Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. World J. Gastroenterol. 2009, 15:4653-4658.
11. Guo C., Zhang C., Li L., Wang Z., Xiao W., Yang Z. Hypoglycemic and hypolipidemic effects of oxymatrine in high-fat diet and streptozotocin-induced diabetic rats. Phytomedicine 2014, 21:807-814.
12. Ha T.J., Yang M.S., Jang D.S., Choi S.U., Park K.H. Inhibitory activity of flavanone derivatives isolated from Sophora flavescens for melanogenesis. Bull. Korean Chem. Soc. 2001, 22:97-99.
13. Han J., Sun M., Cui Y., Wang T., Zhang W., Guo M., Zhou Y., Liu W., Zhang M., Duan J., Xiong S., Yao M., Yan X. Kushen flavonoids induce apoptosis in tumor cells by inhibition of NF-kappaB activation and multiple receptor tyrosine kinase activities. Phytother. Res. 2007, 21:262-268.
14. Heddle J.A., Stuart E., Salamone M.F. The Bone Marrow Micronucleus Test in Handbook of Mutagenicity test Procedures 1984, 441-457. Elsevier, Amsterdam. B.J. Kilbey, M. Legator, W. Nichols, C. Ramel (Eds.).
15. Hu Z.L., Zhang J.P., Qian D.H., Lin W., Xie W.F., Zhang X.R., Chen W.Z. Effects of matrine on mouse splenocyte proliferation and release of interleukin-1 and -6 from peritoneal macrophages in vitro. Zhongguo Yao Li Xue Bao 1996, 17:259-261.
16. Hwang J.S., Lee S.A., Hong S.S., Lee K.S., Lee M.K., Hwang B.Y., Ro J.S. Monoamine oxidase inhibitory components from the roots of Sophora flavescens. Arch. Pharmacal Res. 2005, 28:190-194.
17. Jung H.J., Kang S.S., Hyun S.K., Choi J.S. In vitro free radical and ONOO-scavengers from Sophora flavescens. Arch. Pharmacal Res. 2005, 28:534-540.
18. Kang T.H., Jeong S.J., Ko W.G., Kim N.Y., Lee B.H., Inagaki M., Miyamoto T., Higuchi R., Kim Y.C. Cytotoxic lavandulyl flavanones from Sophora flavescens. J. Nat. Prod. 2000, 63:680-681.
19. Kim Y.K., Min B.S., Bae K.H. A cytotoxic constituent from Sophora flavescens. Arch. Pharmacal Res. 1997, 20:342-345.
20. Kim D.W., Chi Y.S., Son K.H., Chang H.W., Kim J.S., Kang S.S., Kim H.P. Effects of Sophoraflavanone G, a prenylated flavonoid from Sophora flavescens, on cyclooxygenase-2 and in vivo inflammatory response. Arch. Pharmacal Res. 2002, 25:329-335.
21. Kim S.J., Son K.H., Chang H.W., Kang S.S., Kim H.P. Tyrosinase inhibitory prenylated flavonoids from Sophora flavescens. Biol. Pharm. Bull. 2003, 26:1348-1350.
22. Ko E., Lee Y., Park N., Cho C., Yim Y.N., Kim J., Kim Y.S., Kim D., Shin M.K., Hong M.C., Bae H. Sophorae radix reduces autoimmune response in NZB/w F1 systemic lupus erythematosus mouse model. Lupus 2007, 16:335-341.
23. Kuroyanagi M., Arakawa T., Hirayama Y., Hayashi T. Antibacterial and antiandrogen flavonoids from Sophora flavescens. J. Nat. Prod. 1999, 62:1595-1599.
24. Kwon K.B., Park C.S., Kim I.G., Kim H.G., Choi K.B., Kim Y.B. Effects of Sophorae radix extract in rat cardiac endothelial cells. Korean J. Orient. Physiol. Pathol. 2003, 17:220-224.
25. Kwon K.B., Kim E.K., Lim J.G., Shin B.C., Song Y.S., Seo E.A., Ahn K.Y., Song B.K., Ryu D.G. Sophorae radix extract inhibits high glucose-induced vascular cell adhesion molecule-1 up-regulation on endothelial cell line. Clin. Chim. Acta 2004, 348:79-86.
26. Lee H.S., Park K.H., Kwon K.B., Mun B.S., Song C.M., Song Y.S. Anti-allergic activity of the Sophorae radix water extract in experimental animals. Am. J. Chin. Med. 2001, 29:129-139.
27. Lee S.M., Park N.S., Jin B.R., Kang H.S., Jung J.H., Park E. Effects of Paecilomyces tenuipes cultivated in egg yolk on lipid metabolism in rats on a high fat-cholesterol diet. J. Med. Food 2006, 9:214-222.
28. Liu Y., Xu Y., Ji W., Li X., Sun B., Gao Q., Su C. Anti-tumor activities of matrine and oxymatrine: literature review. Tumour Biol. 2014, 35:5111-5119.
29. McHutchison J.G., Manns M.P., Longo D.L. Definition and management of anemia in patients infected with hepatitis C virus. Liver Int. 2006, 26:389-398.
30. Ministry of Food and Drug Safety (MFDS), 2005. Good laboratory practice regulation for non-clinical laboratory studies (Notification No. 2005-79).
31. OECD, 1997a. OECD Guideline for Testing of Chemicals, Test No. 471: Bacterial Reverse Mutation test.
32. OECD, 1997b. OECD Guideline for Testing of Chemicals, Test No. 473: In vitro Mammalian Chromosome Aberration Test.
33. OECD, 1997c. OECD Guideline for Testing of Chemicals, Test No. 474: Mammalian Erythrocyte Micronucleus Test.
34. OECD, 1998. OECD Guideline for Testing of Chemicals, Test No. 408: Repeated dose 90-day oral toxicity study in rodents.
35. Ou M. English Manual of Common-Used in Traditional Chinese Medicine 1992, Joint Publishing, Hong Kong, (pp. 372-373).
36. Ryu S.Y., Lee H.S., Kim Y.K., Kim S.H. Determination of isoprenyl and lavandulyl positions of flavonoids from Sophora flavescens by NMR experiment. Arch. Pharmacal Res. 1997, 20:491-495.
37. Shi L.J., Shi L., Song G.Y., Zhang H.F., Hu Z.J., Wang C., Zhang D.H. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα). Eur. J. Pharmacol. 2013, 714:89-95.
38. Son J.K., Park J.S., Kim J.A., Kim Y.S., Chung S.R., Lee S.H. Prenylated flavonoids from the roots of Sophora flavescens with tyrosinase inhibitory activity. Planta Med. 2003, 69:559-561.
39. State Administration of Traditional Chinese Medicine Sophora flavescens 1999, 634-643. Shanghai Science and Technology Press, Shanghai. first ed. B. Zhonghua (Ed.).
40. Sun M., Cao H., Sun L., Dong S., Bian Y., Han J., Zhang L., Ren S., Hu Y., Liu C., Xu L., Liu P. Antitumor activities of kushen: literature review. Evid. Based Complement. Altern. Med. 2012, 2012:373219.
41. Tan H.R., Zhang B.H. Experimental study of the anti-inflammatory effect of matrine. Zhong Xi Yi Jie He Za Zhi 1985, 5(108-110):169.
42. Wang Y. Research progress on chemical constituents, preparative separation and quality of Sophora flavescens. Chin. Trad. Pat. Med. 1997, 19:39-41.
43. Wang B.E. Treatment of chronic liver diseases with traditional Chinese medicine. J. Gastroenterol. Hepatol. 2000, 15(Suppl.):E67-E70.
44. Yagi A., Fukunaga M., Okuzako N., Mifuchi I., Kawamoto F. Antifungal substances from Sophora flavescens. Jpn. J. Pharmacogn. 1989, 43:343-347.
45. Yin X.J., Liu D.X., Wang H.C., Zhou Y. A study on the mutagenicity of 102 raw pharmaceuticals used in Chinese traditional medicine. Mutat. Res. 1991, 260:73-82.
46. Yu Q., Cheng N., Ni X. Identifying 2 prenylflavanones as potential hepatotoxic compounds in the ethanol extract of Sophora flavescens. J. Food Sci. 2013, 78:T1830-T1834.
47. Zhu J.S., Halpern G.M., Jones K. The scientific rediscovery of an ancient Chinese herbal medicine: Cordyceps sinensis: part I. J. Altern. Complement. Med. 1998, 4:289-303.
48. Zhu J.S., Halpern G.M., Jones K. The scientific rediscovery of a precious ancient Chinese herbal regimen: Cordyceps sinensis: part II. J. Altern. Complement. Med. 1998, 4:429-457.